Canada Rising – The Next Frontier in Clinical Trials

What makes Canada a reliable location for clinical research and how trusted, local expertise can help overcome key barriers.

20

January

  • 3PM London / 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

Clinical trials are entering their most turbulent period yet. Rising costs, shifting regulations, geopolitical tensions, and increasingly complex trial designs are reshaping where and how research gets done. Sponsors face mounting pressure from data-heavy studies and shrinking patient pools to supply-chain instability and policy changes that threaten R&D investment.

Amid this disruption, Canada is emerging as a strategic safe haven. Already a top-ten clinical trial destination, and ranking 5th globally for planned trials as of December 2024, Canada offers rare stability, strong regulatory alignment with the EU, and proximity to the world’s largest trial market, the US. As tariffs, policy shifts, and global uncertainty raise risks elsewhere, Canada’s appeal as a cost-effective, reliable research hub is accelerating.

Join members of global supply chain solutions provider, Oximio, in this new webinar as they explore how global clinical trial pressures are reshaping site selection, why sponsors are rethinking geographic strategy, and where Canada fits into the future of global clinical research.

A must-attend webinar for those planning clinical trials in North America, Oximio delivers practical insights and expert guidance to help navigate logistical challenges within the region.

You’ll hear from Zayheda Khan, Oximio’s Chief Commercial Officer and UK Managing Director and Kaitlin Guarasci, Managing Director of Oximio BARL Canada.

  • Canada’s position in the global clinical trial stage, including key sponsors, therapies & trial phase.
  • What makes Canada reliable hub for clinical trials.
  • Key challenges and how these can be overcome
  • Hear from members of the Oximio team, who will share advice and experiences.

Speakers

Select a speaker to learn more

Back
Zayheda Khan
Chief Commercial Officer and UK Managing Director

Zayheda Khan was appointed Chief Commercial Officer in December 2022 and UK Managing Director in October 2024.

She has more than 20 years experience in a variety of roles within the clinical trial sectors including preclinical, clinical, proposal and budgeting, procurement and programme management.

Zayheda oversees the Marketing, Sales/KAM, Commercial Operations, Procurement and Project Management functions with the aim of assessing customer needs and providing cost-effective tailor-made solutions.

She is also responsible for the commercial data analysis for accurate forecasts and opportunity pipeline management and her organisation is driven to develop customer partnerships and drive forward the success of the commercial projects in an ever-changing clinical trial landscape.

Zayheda has a Bachelor’s Degree from the University of Central Lancashire and Master and PhD Degrees in Pharmacology from The University of Bradford.

Next speaker
Back
Kaitlin Guarasci
Managing Director, Oximio BARL Canada

Kaitlin has been with Oximio BARL Canada for more than 10 years. As Managing Director, she oversees the planning, direction, and management of operations, while also guiding the organization’s strategic vision and future growth.

She holds a Bachelor of Arts from Brock University, a Pharmacy Technician Diploma from Niagara College, and an MBA from Athabasca University. With this diverse academic background, Kaitlin ensures that operations run compliantly, efficiently, and with customer care at the forefront.

Next speaker

Enquiry